Stryker (NYSE:SYK) said today that paid $52 million (£35.6 million) in cash for SIW Holdings subsidiary Stanmore Implants, which makes medical devices for limb salvage in patients with orthopedic cancers.
“The acquisition of Stanmore Implants provides Stryker with differentiated technologies designed to provide the most effective solutions for orthopedic oncology surgeons. This addition underscores Stryker’s commitment to our core joint replacement business and expands our presence in the global orthopedic oncology market,” Stryker Orthopaedics president David Floyd said in prepared remarks.
“The combination of Stryker’s commitment to orthopedic oncology and Stanmore’s novel orthopedic oncology solutions provides a unique opportunity to impact a broader group of patients globally,” added Stanmore Implants CEO Michael Mainelli.
The 2 companies share a history thanks to Stryker’s buyout of Mako Surgical; in 2013 Stanmore agreed to exit robotics entirely in order to settle patent infringement complaints filed by Mako.
Elstree, U.K.-based Stanmore drew a U.S. import ban from the FDA last year due to problems flagged in a warning letter from the federal safety watchdog.
The post Stryker pays $52m for Stanmore Implants appeared first on MassDevice.
from MassDevice http://ift.tt/2498dFD
Cap comentari:
Publica un comentari a l'entrada